Inactive Instrument

Analyst Reco. ORCHAR Nasdaq

Equities

US68570P1012

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

Cantor Fitzgerald Downgrades Orchard Therapeutics to Neutral From Overweight, Raises Price Target to $16 From $15	23-10-05	MT
Stifel Downgrades Orchard Therapeutics to Hold From Buy, Cuts Price Target to $16 From $22	23-10-05	MT
Oppenheimer Adjusts Orchard Therapeutics Price Target to $34 From $37, Maintains Outperform Rating	23-06-13	MT
Cantor Fitzgerald Adjusts Orchard Therapeutics' Price Target to $15 From $3, Keeps Overweight Rating	23-03-28	MT
Oppenheimer Adjusts Orchard Therapeutics Price Target to $37 From $5, Maintains Outperform Rating	23-03-13	MT
Barclays Lowers Orchard Therapeutics' Price Target to $4 From $6, Maintains Overweight Rating	22-05-13	MT
Cantor Fitzgerald Lowers Price Target for Orchard Therapeutics to $5 From $9, Maintains Overweight Rating	22-04-01	MT
Stifel Lowers Price Target for Orchard Therapeutics to $5 From $12, Maintains Buy Rating	22-04-01	MT
SMBC Nikko Downgrades Orchard Therapeutics to Neutral From Outperform, Adjusts Price Target to $1 From $8	22-04-01	MT
Cowen Downgrades Orchard Therapeutics to Market Perform From Outperform	22-03-31	MT
Cantor Fitzgerald Assumes Coverage on Orchard Therapeutics With Overweight Rating, $9 Price Target	21-12-29	MT
JPMorgan Downgrades Orchard Therapeutics to Underweight From Neutral	21-11-16	MT
Wedbush Adjusts Price Target for Orchard Therapeutics to $11 From $13, Maintains Outperform Rating	21-11-05	MT
Oppenheimer Adjusts Orchard Therapeutics PT to $13 From $15, Maintains Outperform Rating	21-11-05	MT
ORCHARD THERAPEUTICS : JPMorgan Downgrades Orchard Therapeutics to Neutral From Overweight	21-08-18	MT
ORCHARD THERAPEUTICS : Goldman Sachs Adjusts Orchard Therapeutics PT to $10 From $13, Maintains Buy Rating	21-06-30	MT
ORCHARD THERAPEUTICS : SMBC Nikko Adjusts Orchard Therapeutics PT to $16 From $19, Maintains Outperform Rating	21-06-30	MT
ORCHARD THERAPEUTICS : Cantor Fitzgerald Adjusts Orchard Therapeutics' Price Target to $12 From $17, Reiterates Overweight Rating	21-06-30	MT
ORCHARD THERAPEUTICS : JPMorgan Adjusts Orchard Therapeutics' Price Target to $14 From $15, Reiterates Overweight Rating	21-06-30	MT
ANALYST RECOMMENDATIONS : Apple, FedEx, Intellia Therapeutics, Reckitt Benckiser, XPO Logistics...	21-06-30

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. ORCHAR Nasdaq

Equities

US68570P1012

Analyst Reco.

Filters